New Agents in Clinical Oncology. 24 November 2006, London, UK.
Martin
Stewart
S
University of Nottingham, Department of Clinical Oncology, Nottingham University Hospitals NHS Trust, City Hospital Campus, Nottingham, NG7 2RD, UK. stewart.martin@nottingham.ac.uk
D019797:3-Iodobenzylguanidine / Q000627:therapeutic use; D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D000972:Antineoplastic Agents, Phytogenic / Q000627:therapeutic use; D001632:Bibenzyls / Q000627:therapeutic use; D003131:Combined Modality Therapy; D004791:Enzyme Inhibitors / Q000627:therapeutic use; D006801:Humans; D008495:Medical Oncology / Q000639:trends*; D009369:Neoplasms / Q000188:drug therapy* / Q000378:metabolism / Q000532:radiotherapy; D050484:Norepinephrine Plasma Membrane Transport Proteins / Q000096:biosynthesis; D000067856:Poly(ADP-ribose) Polymerase Inhibitors; D040901:Proteomics; D013267:Stilbenes / Q000627:therapeutic use; D013879:Thioredoxins / Q000037:antagonists & inhibitors; D019772:Topotecan / Q000627:therapeutic use
D000970:Antineoplastic Agents; D000972:Antineoplastic Agents, Phytogenic; D001632:Bibenzyls; D004791:Enzyme Inhibitors; D050484:Norepinephrine Plasma Membrane Transport Proteins; D000067856:Poly(ADP-ribose) Polymerase Inhibitors; D013267:Stilbenes; D019797:3-Iodobenzylguanidine; D013879:Thioredoxins; D019772:Topotecan; C040105:combretastatin